focus -WSS

focus

author：comprehensive 2025-09-27 13:09:57 - browse：8391

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： STAT Madness 2024: Meet the contenders

focus

explore

WSS

Elisabeth Bik tackles the widespread issue of research misconduct

As biotech industry slumps, bioscience job market is upside down

Are embryos people? Reproductive medicine's future depends on the answer

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Cigna, Humana reportedly in talks to merge

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

The cancer drug shortage isn’t new — and neither are the solutions

BIO selects John Crowley as new CEO

Walensky prepares to leave CDC — and Congress — behind

Ohio train derailment: Experts on toxic chemical risks

Medicare proposal to cover medical devices draws a mixed reaction

Cholera vaccine supplies dangerously low, outbreaks surging

BioMarin wins approval for gene therapy to treat hemophilia A

The EPA's new lead rule: How one expert crunched the numbers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cigna, Humana reportedly in talks to merge

focus

U.K. Biobank has 500,000 peoples' genome sequences available

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Cholera vaccine supplies dangerously low, outbreaks surging

Using force crossed my mind when examining a defiant young patient

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Will the market for weight loss drugs really reach $100 billion?

knowledge

focus

explore

focus